Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme
PaperCitations, authors & open-access status
Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1 citations, 2025 year and gold oa status.
1
Citations
2025
Year
gold
OA Status